Real-World study tracks new prostate cancer combo in 1,600 men
NCT ID NCT07344779
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers want to see how many men reach very low PSA levels after one year and how the treatment affects their daily lives. The goal is to understand how well this drug works outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Many Locations
Multiple Locations, Belgium
-
Many Locations
Multiple Locations, Finland
-
Many Locations
Multiple Locations, France
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Greece
-
Many Locations
Multiple Locations, Israel
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Lithuania
-
Many Locations
Multiple Locations, Norway
-
Many Locations
Multiple Locations, Poland
-
Many Locations
Multiple Locations, Portugal
-
Many Locations
Multiple Locations, Saudi Arabia
-
Many Locations
Multiple Locations, Spain
-
Many Locations
Multiple Locations, Sweden
-
Many Locations
Multiple Locations, Switzerland
-
Many Locations
Multiple Locations, United Kingdom
Conditions
Explore the condition pages connected to this study.